With recent studies from Oregon State University raising essential points about drug safety and research transparency in an era when the U.S. Food and Drug Administration seems to be approving drugs after fewer trials (accelerated approval) and releasing less data from those trials, one experienced principal investigator cautions that public perceptions of clinical research may take a hit.
With a new international guidance open for public comments, stakeholders in digital, hybrid, and fully decentralized clinical trials (DCTs) may feel a growing urgency to harmonize global regulations to prevent any roadblocks to adopting the technologies necessary to achieve the benefits of this approach.
This study explored the experiences of clinical research principal investigators (PIs) in addressing diversity in clinical trials. The PI respondents, recruited through social media and professional networks, shared their insights through interviews.
Digital medicine represents a paradigm change in oncology research by harnessing technological breakthroughs to address the constraints of traditional clinical trial procedures. Researchers may collect huge amounts of patient-generated health data by adding digital tools into the clinical trial process.
This article presents a fictionalized scenario and details to illustrate career options worth considering in contract research organizations and other settings.